Psychiatric management of acute myocardial infarction in the coronary care unit

The American Journal of Cardiology
T A Stern

Abstract

Failure to recognize and treat the psychiatric complications of myocardial infarction (MI) may aggravate the underlying cardiac condition and interfere with its treatment. The timing and manifestations of several distinct psychiatric conditions that commonly accompany the acute phase of MI (anxiety, depression, delirium, and behavioral abnormalities secondary to a person's premorbid character style) will be reviewed. In addition, the importance of psychological risk factors for the development of coronary artery disease (e.g., life stress and the Type A behavior pattern) and the impact of denial on the cardiac patient's condition will be discussed. Management strategies that include nonpharmacologic (i.e., support, reassurance, brief psychotherapy and cardiac rehabilitation) and psychopharmacologic interventions (e.g., the rational use of benzodiazepines, antidepressants and neuroleptic agents) for psychiatric conditions in the MI patient will be provided. Postdischarge issues that occur in both the patient and his or her family are outlined, and the enrollment in cardiac rehabilitation programs is encouraged.

References

May 20, 1976·The New England Journal of Medicine·B Lown, R L Verrier
Sep 1, 1979·General Hospital Psychiatry·D L DudleyP J Loebel
Mar 1, 1978·Journal of Behavioral Medicine·R M Suinn, L J Bloom
Feb 1, 1979·The American Journal of Psychiatry·P T DonlonE Amsterdam
May 26, 1977·The American Journal of Cardiology·B LownS H Rabinowitz
Feb 1, 1975·Metabolism: Clinical and Experimental·M FriedmanR H Rosenman
Jan 1, 1987·Psychosomatics·T A SternN H Cassem
Jun 1, 1986·The American Journal of Psychiatry·G Rodin, K Voshart
Dec 1, 1986·The American Journal of Psychiatry·G L Fricchione, S C Vlay
Apr 1, 1986·Psychosomatics·E S Geringer, T A Stern
Jul 1, 1971·The American Journal of Psychiatry·C B Bilodeau, T P Hackett
Jun 6, 1974·The New England Journal of Medicine·C D JenkinsS J Zyzanski
May 1, 1969·British Heart Journal·C Papp
Mar 1, 1972·Psychosomatic Medicine·D Hay, D Oken
Jul 1, 1971·Annals of Internal Medicine·N H Cassem, T P Hackett
Nov 1, 1969·The American Journal of Cardiology·T P Hackett, N H Cassem
Aug 1, 1971·British Medical Journal·I T Pratt
Aug 1, 1967·Journal of Psychosomatic Research·T H Holmes, R H Rahe
Aug 28, 1967·JAMA : the Journal of the American Medical Association·D L Parker, J R Hodge
Jan 1, 1984·Annual Review of Physiology·R L Verrier, B Lown
Jan 1, 1984·Journal of Psychosomatic Research·L HorlickR Baltzan
Jan 1, 1984·Journal of Psychosomatic Research·J R Jennings, W P Follansbee
Jun 1, 1983·Psychosomatic Medicine·J E DimsdaleL H Hartley
Nov 1, 1980·Psychosomatic Medicine·E M CottingtonL H Kuller
Jul 1, 1974·International Journal of Psychiatry in Medicine·M A IbrahimD Dean
Feb 5, 1955·British Medical Journal·K A JARVINEN
Mar 1, 1965·Journal of Psychosomatic Research·W W TOLSONJ R FISHMAN
Oct 4, 1952·Journal of the American Medical Association·W P HARVEY, S A LEVINE

❮ Previous
Next ❯

Citations

Apr 1, 1995·Journal of Psychosomatic Research·J J Thomas
Mar 17, 2004·Heart & Lung : the Journal of Critical Care·Kyungeh AnDebra K Moser
Mar 18, 2006·Heart & Lung : the Journal of Critical Care·Havva Tel, Hatice Tel
Dec 14, 2002·The American Journal of Cardiology·Jacqueline J M H StrikAdriaan Honig
Dec 9, 1994·Clinical Intensive Care : International Journal of Critical & Coronary Care Medicine·F PochardJ F Dhainaut
Mar 30, 2021·Circulation Journal : Official Journal of the Japanese Circulation Society·Toshihisa AnzaiUNKNOWN Japanese Circulation Society Joint Working Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here